FDA approves new treatment for secondary hyperparathyroidism

Image from pharmpro.com

Image from pharmpro.com

The US Food and Drug Administration has approved a new treatment for secondary hyperparathyroidism which is administered at the end of a dialysis session.  See the link below for the full story.

FDA approves new treatment for secondary hyperparathyroidism

Profile photo of Rob Finnigan

I’m an ADPKD patient who was lucky enough to have a transplant in 2003 after only eleven months of dialysis. I'm the north-west Patient Advocacy & Support Officer for the BKPA and my interests, other than my role within GMKIN, include sport, music and politics . Follow me on Twitter: @finnigr

This entry was posted in . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *